BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
October 01 2024 - 5:00AM
- Provides updates on BioNTech’s strategy to scale and deploy
AI-capabilities across the immunotherapy pipeline
- Highlights InstaDeep’s new near exascale supercomputer, Kyber,
with the aim of enabling BioNTech to compute at scale
- Unveils novel AI Bayesian Flow Network (“BFN”) models for
protein sequence generation
- Highlights progress in deploying AI across BioNTech’s
immunotherapy pipeline, including in immunohistochemistry, DNA/RNA
sequencing, proteomics, protein design, and lab functional
validation
LONDON, United Kingdom, October 1, 2024
(GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”
or “the Company”), alongside its artificial intelligence (“AI”)
subsidiary InstaDeep Ltd. (“InstaDeep”), today presents
an overview of its AI approach during an edition of the Company’s
Innovation Series, AI Day.
“At BioNTech, we are at the forefront of
integrating advanced AI to revolutionize individualized medicine.
With our in-house AI specialist, InstaDeep, we are pioneering the
use of artificial intelligence to develop personalized vaccines and
targeted therapies,” said Prof. Ugur Sahin, M.D., CEO and
Co-Founder of BioNTech. “By introducing state-of-the-art
technologies such as our BFN generative protein model and
incorporating AI capabilities across our immunotherapy pipeline, we
are unlocking the full potential of AI to deliver innovative
vaccines and cancer treatments to patients worldwide”.
“BioNTech and InstaDeep, as a biotechnology
powerhouse with a dedicated AI unit, are uniquely positioned at the
intersection of biotechnology and AI,” said Karim Beguir, CEO
and Co-Founder of InstaDeep, a BioNTech company. “Working
closely together and combining expertise from AI research, high
performance computing, software and biology is accelerating
innovation. A key focus of this collaboration is our DeepChain™
multiomics design platform. DeepChain™ is now open for external
partnerships, after successful application to several projects,
including the mRNA-encoded antibody RiboMab™ platform. We are
excited to harness breakthroughs in both AI and biotechnology
synergistically.’’
As part of the event, BioNTech will showcase the
Company’s approach to AI capability scaling and deployment across
BioNTech’s pipeline. These updates will cover the introduction of a
new near exascale supercomputer, the launch of a novel BFN
generative model, and multiple updates on the deployment of AI
across BioNTech’s immunotherapy pipeline.
The live webcast of the event will be available
via this link and will begin at 3:00 pm CEST (2:00 pm BST,
9:00 am EDT). A replay of the webcast will be available shortly
after the event’s conclusion and archived on BioNTech’s website for
one year.
About BioNTechBiopharmaceutical New
Technologies (BioNTech) is a global next generation immunotherapy
company pioneering novel therapies for cancer and other serious
diseases. BioNTech exploits a wide array of computational discovery
and therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor (CAR) T cells,
several protein-based therapeutics, including bispecific immune
checkpoint modulators, targeted cancer antibodies and antibody-drug
conjugate (ADC) therapeutics, as well as small molecules. Based on
its deep expertise in mRNA vaccine development and in-house
manufacturing capabilities, BioNTech and its collaborators are
developing multiple mRNA vaccine candidates for a range of
infectious diseases alongside its diverse oncology pipeline.
BioNTech has established a broad set of relationships with multiple
global and specialized pharmaceutical collaborators, including
Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the
Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and
Regeneron.
For more information, please visit
www.BioNTech.com.
Forward-Looking StatementsThis press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including, but not limited to, statements concerning the impact of,
and expectations regarding, BioNTech’s AI capabilities and future
research and development activities. In some cases, forward-looking
statements can be identified by terminology such as “will,” “may,”
“should,” “expects,” “intends,” “plans,” “aims,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential,” “continue,” or
the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on
BioNTech’s current expectations and beliefs of future events, and
are neither promises nor guarantees. You should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond BioNTech’s control and which could cause actual
results to differ materially and adversely from those expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to: the uncertainties
inherent in research and development,; competition from other
product candidates BioNTech’s and its counterparties’ ability
to manage and source necessary energy resources; BioNTech’s ability
to identify research opportunities and discover and develop
investigational medicines; the ability and willingness of
BioNTech’s third-party collaborators to continue research and
development activities relating to BioNTech's development
candidates and investigational medicines; BioNTech’s ability to
manage its development; regulatory developments in the United
States and other countries; BioNTech’s ability to effectively scale
its production capabilities and manufacture its products and
product candidates; risks relating to the global financial system
and markets; and other factors not known to BioNTech at this
time.
You should review the risks and uncertainties
described under the heading “Risk Factors” in BioNTech’s Report on
Form 6-K for the period ended June 30, 2024 and in subsequent
filings made by BioNTech with the SEC, which are available on the
SEC’s website at www.sec.gov. These forward-looking statements
speak only as of the date hereof. Except as required by law,
BioNTech disclaims any intention or responsibility for updating or
revising any forward-looking statements contained in this press
release in the event of new information, future developments or
otherwise.
CONTACTS
Investor RelationsMichael
HorowiczInvestors@biontech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Nov 2023 to Nov 2024